TScan Therapeutics's market cap is currently $116.88M. The company's EPS TTM is $-1.258; its P/E ratio is ―; TScan Therapeutics is scheduled to report earnings on March 5, 2025, and the estimated EPS forecast is $-0.32. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 21.05M	$ 13.54M	$ 10.14M	$ 1.08M	$ 0.00
Gross Profit	$ -67.10M	$ 8.40M	$ 6.81M	$ -19.49M	$ -519.00K
Operating Income	$ -93.46M	$ -66.64M	$ -48.64M	$ -26.23M	$ -14.21M
EBITDA	$ -80.10M	$ -59.91M	$ -45.30M	$ -25.00M	$ -13.69M
Net Income	$ -89.22M	$ -65.81M	$ -48.63M	$ -26.02M	$ -13.11M
Balance Sheet
Cash & Short-Term Investments	$ 192.04M	$ 120.03M	$ 161.41M	$ 34.79M	$ 41.76M
Total Assets	$ 272.15M	$ 199.09M	$ 188.11M	$ 49.74M	$ 49.38M
Total Debt	$ 92.43M	$ 85.98M	$ 6.04M	$ 7.43M	$ 4.89M
Net Debt	$ -40.93M	$ -34.04M	$ -155.36M	$ -27.36M	$ -36.88M
Total Liabilities	$ 121.28M	$ 99.66M	$ 27.33M	$ 92.20M	$ 66.52M
Stockholders' Equity	$ 150.87M	$ 99.43M	$ 160.78M	$ -42.46M	$ -17.14M
Cash Flow
Free Cash Flow	$ -64.50M	$ -70.73M	$ -58.62M	$ -7.26M	$ -13.77M
Operating Cash Flow	$ -61.36M	$ -66.50M	$ -48.68M	$ -3.02M	$ -12.52M
Investing Cash Flow	$ -60.76M	$ -4.22M	$ -9.94M	$ -4.24M	$ -1.25M
Financing Cash Flow	$ 135.44M	$ 29.36M	$ 189.67M	$ 288.00K	$ 34.81M

Currency in USD

TScan Therapeutics Earnings and Revenue History

Income Statement >

TScan Therapeutics Debt to Assets

Balance Sheet >

TScan Therapeutics Cash Flow

Cash Flow >

TScan Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing